Metabolic resistance of Abeta3pE-42, epitope of the anti-Alzheimer therapeutic antibody, donanemab
Metabolic resistance of Abeta3pE-42, epitope of the anti-Alzheimer therapeutic antibody, donanemab
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Amyloid beta peptide (Abeta) starting with pyroglutamate (pE) at position 3 and ending at position 42 (Abeta3pE-42) is a dominant species that accumulates in Alzheimer's disease (AD) brain. Consistently, a therapeutic antibody raised against this species, donanemab, has succeeded in recent clinical trials. While the primary Abeta species produced p...
Alternative Titles
Full title
Metabolic resistance of Abeta3pE-42, epitope of the anti-Alzheimer therapeutic antibody, donanemab
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2920341934
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2920341934
Other Identifiers
DOI
10.1101/2024.01.30.578111
How to access this item
https://www.proquest.com/docview/2920341934?pq-origsite=primo&accountid=13902
